| For the year ended | For the year ended | ||
| 31 March 2024 | 31 March 2023 | ||
| US$ | US$ | ||
| (Loss)/income | |||
Net losses on financial assets at fair value through profit or loss | 5 | ( | ( |
Dividend income | 7 | ||
Other income | |||
Net foreign exchange losses | ( | ( | |
Total (loss)/income | ( | ||
| Expenses | |||
Director, Executive team and employee costs | 10 | ||
Share-based payments | 10 | ||
Audit fees | 8 | ||
Investor relations and PR consultancy fees | |||
Legal and professional fees | |||
Office support fees | |||
Administration fees | 10 | ||
Travel and marketing fees | |||
Other expenses | |||
Total expenses | |||
(Loss)/profit for the year before tax | ( | ||
Tax (charge)/credit | 11 | ( | |
(Loss)/profit for the year | ( | ||
| Other comprehensive income/(loss) | |||
| Items that might be reclassified to profit or loss | |||
Foreign exchange differences on translation of foreign operations | ( | ||
Total comprehensive (loss)/income for the year | ( | ||
Earnings per Ordinary Share for (loss)/profit attributable to the Company’s shareholders: | |||
Basic (loss)/earnings per Ordinary Share | 14 | ( | |
Diluted (loss)/earnings per Ordinary Share | 14 | ( |
| Foreign | |||||||
| currency | |||||||
| Share | Treasury | Retained | Other | translation | |||
| capital | shares | earnings | reserves | reserve | Total equity | ||
| Note | US$ | US$ | US$ | US$ | US$ | US$ | |
At 1 April 2022 | |||||||
| Total comprehensive income: | |||||||
Profit for the year | |||||||
Other comprehensive loss | ( | ( | |||||
| Total comprehensive income | |||||||
for the year | ( | ||||||
Transactions with shareholders: | |||||||
Dividends paid | 4 | ( | ( | ||||
Share-based awards | 10 | ||||||
Total transactions with shareholders | ( | ( | |||||
At 31 March 2023 | ( | ||||||
At 1 April 2023 | ( | ||||||
Total comprehensive loss: | – | ||||||
Loss for the year | ( | ( | |||||
Other comprehensive income | |||||||
Total comprehensive loss for the year | ( | ( | |||||
Transactions with shareholders: | |||||||
Dividends paid | 4 | ( | ( | ||||
Share-based awards | 10 | ||||||
Treasury shares purchased | 12 | ( | ( | ||||
Total transactions with shareholders | ( | ( | ( | ||||
At 31 March 2024 | ( |
| 31 March 2024 | 31 March 2023 | ||
| US$ | US$ | ||
| Non-current assets | |||
Financial assets at fair value through profit or loss | 5 | ||
Property, plant and equipment | |||
Total non-current assets | |||
| Current assets | |||
Cash | |||
Trade and other receivables | |||
Total current assets | |||
Total assets | |||
| Current liabilities | |||
Trade and other payables | 8 | ||
Total current liabilities | |||
Net assets | |||
| Equity | |||
Share capital | 12 | ||
Treasury shares | 12 | ( | |
Retained earnings | |||
Other reserves | |||
Foreign currency translation reserve | ( | ||
Total equity | |||
Number of Ordinary Shares | 12 | ||
Net asset value per Ordinary Share |
| For the year ended | For the year ended | ||
| 31 March 2024 | 31 March 2023 | ||
| US$ | US$ | ||
| Cash flows from operating activities | |||
(Loss)/profit for the year after tax | ( | ||
| Adjustments for: | |||
Net losses on financial assets at fair value through profit or loss | 5 | ||
Share-based awards | 10 | ||
Net foreign exchange losses | |||
Depreciation | |||
Increase in trade and other receivables | ( | ( | |
(Decrease)/increase in trade and other payables | ( | ||
Net cash transfers from TMI Holdco Limited | 5 | ||
Net cash transfers to TMI Holdco Limited | 5 | ( | |
Net cash flows from operating activities | |||
| Cash flows used in investing activities | |||
Purchase of property, plant and equipment | ( | ( | |
Net cash flows used in investing activities | ( | ( | |
| Cash flows used in financing activities | |||
Dividends paid | 4 | ( | ( |
Purchase of treasury shares | 12 | ( | |
Net cash flows used in financing activities | ( | ( | |
Net (decrease)/increase in cash | ( | ||
Cash at beginning of year | |||
Effect of foreign exchange rate changes during the year | ( | ( | |
Cash at end of year | |||
| The accompanying notes on pages 112–143 form an integral part of the Consolidated Financial Statements. |